Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis & Investment Frameworks
Amylyx Pharmaceuticals, Inc. (AMLX) stock analysis on Invetso. Review Amylyx Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Amylyx Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Amylyx Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $3.70B
- Revenue: $N/A
- ROE: -41.54%
- ROIC: -23.16%
- Dividend Yield: N/A
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.